Yüklüyor......
Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105
The FDA approval of bevacizumab (Avastin(®), Genentech/Roche), a monoclonal antibody raised against human VEGF-A, as second-line therapy for colon and lung carcinoma validated the approach of targeting human tumors with angiogenesis inhibitors. While the VEGF/VEGFR pathway is a viable target for ant...
Kaydedildi:
| Yayımlandı: | Cancer Immunol Immunother |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Springer-Verlag
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4438988/ https://ncbi.nlm.nih.gov/pubmed/21431419 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00262-011-1002-x |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|